GlaxoSmithKline is planning to cut 850 research and development jobs in Britain and the US, in a bid to improve productivity.

The move is in addition to 350 job cuts announced by the world’s second biggest drugmaker in June.

“Following a recent review of business operations, we have started consultation on proposals which could impact 850 roles within R&D in the UK and the US,” a spokeswoman said.

In July, GlaxoSmithKline said it would divide its research and development, which is in seven centres, into smaller groups of up to 80 scientists. The groups will have to apply for funding to a central investment board.